Form 4 for ESLA Estrella Immunopharma, Inc.
Accepted 2026-08-26 19:23:37 ET · period of report 2026-08-25 · accession 0001996255-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-26 19:23 | 2026-08-25 | ESLA | Liu Cheng | CEO, Dir | M - OptEx | $0.815 | +100.0K | 397.4K | +34% | +$81.5K |
| D | 2026-08-26 19:23 | 2026-08-25 | ESLA | Liu Cheng | CEO, Dir | M - OptEx | $0.00 | +100.0K | 900.0K | +12% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.0001 per share | 2026-08-25 | M | A | 100,000 | $0.815 | 397,437 | D | — | — | (F1) Represents the exercise price per share paid by the Reporting Person upon the exercise of the stock options reported in Table II. (F2) Reflects the 297,437 shares of Common Stock directly beneficially owned as reported on the Reporting Person's most recent Form 4, plus the 100,000 shares acquired upon the reported exercise. |
| 2 | Derivative | Incentive Stock Option | 2026-08-25 | M | A | 100,000 | $0.00 | 900,000 | D | $0.815 · 2024-10-31 to 2034-10-29 | 100,000 Common Stock | (F3) Represents incentive share options granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan, of which twenty-five percent (25%) was immediately exercisable on the date of grant, with the remainder vesting in equal monthly installments of 1/48th of the total award on each monthly anniversary of October 30, 2024. The options were vested as to the shares exercised. (F4) Not applicable. The reported transaction is the exercise of the stock option for the exercise price set forth in Column 2. No separate consideration was paid or received for the derivative security. (F3) Represents incentive share options granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan, of which twenty-five percent (25%) was immediately exercisable on the date of grant, with the remainder vesting in equal monthly installments of 1/48th of the total award on each monthly anniversary of October 30, 2024. The options were vested as to the shares exercised. |